Edgar Filing: RespireRx Pharmaceuticals Inc.

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Margolis Jeff Eliot

2. Issuer Name and Ticker or Trading Symbol
RespireRx Pharmaceuticals Inc. [RSPI]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
VP, Treasurer & Secretary

(Last)

(First)

(Middle)

C/O RESPIRERX PHARMACEUTICALS INC., 126 VALLEY ROAD, SUITE C

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2016

(Street)

GLEN ROCK, NJ 07452

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/16/2016		J⁽¹⁾		5,000,000	D	$ 0 ⁽¹⁾	10,134,944	D
Common Stock	06/16/2016		J⁽¹⁾		5,000,000	A	$ 0 ⁽¹⁾	5,000,000	I	By Spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Common Stock Warrants (right to buy)

$ 0.021

06/16/2016

J⁽¹⁾

787,363

⁽²⁾

09/30/2020

Common Stock

787,363

$ 0 ⁽¹⁾

787,363

Common Stock Warrants (right to buy)

$ 0.021

06/16/2016

J⁽¹⁾

787,363

⁽²⁾

09/30/2020

Common Stock

787,363

$ 0 ⁽¹⁾

787,363

By Spouse

Common Stock Options (to purchase shares of Common Stock)

$ 0.0227

06/16/2016

J⁽¹⁾

9,000,000

⁽³⁾

03/31/2021

Common Stock

9,000,000

$ 0 ⁽¹⁾

15,000,000

Common Stock Options (to purchase shares of Common Stock)

$ 0.0227

06/16/2016

J⁽¹⁾

9,000,000

⁽³⁾

03/31/2021

Common Stock

9,000,000

$ 0 ⁽¹⁾

9,000,000

By Spouse

Common Stock Options (to purchase shares of Common Stock)

$ 0.0197

06/16/2016

J⁽¹⁾

3,000,000

⁽⁴⁾

08/18/2022

Common Stock

3,000,000

$ 0 ⁽¹⁾

7,000,000

Common Stock Options (to purchase shares of Common Stock)

$ 0.0197

06/16/2016

J⁽¹⁾

3,000,000

⁽⁴⁾

08/18/2022

Common Stock

3,000,000

$ 0 ⁽¹⁾

3,000,000

By Spouse

Common Stock Options (to purchase shares of Common Stock)

$ 0.025

06/16/2016

J⁽¹⁾

5,000,000

⁽⁵⁾

06/30/2022

Common Stock

5,000,000

$ 0 ⁽¹⁾

10,000,000

Common Stock Options (to purchase shares of Common Stock)

$ 0.025

06/16/2016

J⁽¹⁾

5,000,000

⁽⁵⁾

06/30/2022

Common Stock

5,000,000

$ 0 ⁽¹⁾

5,000,000

By Spouse

Common Stock Options (to purchase shares of Common Stock)

$ 0.05

06/16/2016

J⁽¹⁾

1,363,637

⁽⁶⁾

07/17/2019

Common Stock

1,363,637

$ 0 ⁽¹⁾

1,363,636

Common Stock Options (to purchase shares of Common Stock)

$ 0.05

06/16/2016

J⁽¹⁾

1,363,637

⁽⁶⁾

07/17/2019

Common Stock

1,363,637

$ 0 ⁽¹⁾

1,363,637

By Spouse

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Margolis Jeff Eliot C/O RESPIRERX PHARMACEUTICALS INC. 126 VALLEY ROAD, SUITE C GLEN ROCK, NJ 07452	X		VP, Treasurer & Secretary

Signatures

/s/ Jeff E. Margolis		06/20/2016
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	All dispositions and acquisitions set forth on this Form 4 reflect estate planning transactions. In each case, securities jointly held by Mr. Margolis and his spouse are being transferred so they are held in the spouse's name only.
(2)	These Warrants were acquired by Mr. Margolis and his spouse in his capacity as President of Aurora Capital LLC, which served as placement agent in the Company's unit offering with each unit consisting of one share of common stock and warrants to purchase two additional shares of common stock, and represent his share of the Placement Agent Warrants awarded at each closing of that transaction. The warrants are currently exercisable.
(3)	These Common Stock Options vest in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016.
(4)	These Common Stock Options vest in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016.
(5)	These Common Stock Options vested in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015, and are all currently vested and exercisable.
(6)	These Common Stock Options vested in three equal installments on July 17, 2014, September 30, 2014 and December 31, 2014, and are all currently vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.